Lista de obras -

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model ⬇️

artículo científico publicado el 4 de noviembre de 2011

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma

artículo científico publicado en 2020

Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression ⬇️

artículo científico publicado el 11 de mayo de 2011

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

artículo científico publicado en 2006

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

artículo científico publicado el 27 de octubre de 2010

Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.

artículo científico publicado en 2018

Chronic Invasive Fungal Rhinosinusitis with Atypical Clinical Presentation in an Immunocompromised Patient

artículo científico publicado en 2020

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations

artículo científico publicado en 2015

Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis ⬇️

artículo científico publicado el 15 de agosto de 2013

Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array ⬇️

artículo científico publicado el 21 de julio de 2012

Cyclosporine A for Chemotherapy-Resistant Subcutaneous Panniculitis-Like T Cell Lymphoma with Hemophagocytic Syndrome ⬇️

artículo científico publicado el 17 de marzo de 2011

Cytogenetic analysis of de novo CD5‐positive diffuse large B‐cell lymphoma ⬇️

artículo científico publicado el 1 de diciembre de 2011

Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome ⬇️

artículo científico publicado el 1 de noviembre de 2011

Deletion or methylation ofCDKN2A/2BandPVT1rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality ⬇️

artículo científico publicado el 9 de mayo de 2013

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.

artículo científico publicado en 2016

Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease

scientific article published on 13 April 2019

Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab ⬇️

artículo científico publicado el 14 de septiembre de 2012

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma

artículo científico publicado en 2020

Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma

artículo científico publicado en 2013

Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.

artículo científico publicado en 2017

Frequent PVT1 Rearrangement and Novel Chimeric Genes PVT1-NBEA and PVT1-WWOX Occur in Multiple Myeloma with 8q24 Abnormality ⬇️

artículo científico publicado el 6 de agosto de 2012

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

artículo científico publicado en 2007

Hematopoietic progenitor cell mobilization using low‐dose cyclophosphamide and granulocyte colony‐stimulating factor for multiple myeloma ⬇️

artículo científico publicado el 27 de junio de 2013

Identification of IGHCδ–BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B‐cell lymphoma/leukemia ⬇️

artículo científico publicado el 13 de enero de 2011

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients

scientific article published on 09 January 2019

Intravascular B-cell lymphoma with hypercalcemia as the initial presentation ⬇️

artículo científico publicado el 3 de noviembre de 2011

Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?

scientific article published on 21 June 2019

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma

scientific article published on 19 June 2020

Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia

artículo científico publicado el 1 de enero de 2013

NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients

artículo científico publicado en 2014

Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy

artículo científico

Pure red cell aplasia caused by parvovirus B19 in two patients without chronic hemolysis ⬇️

artículo científico publicado el 7 de septiembre de 2010

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma ⬇️

artículo científico publicado el 25 de septiembre de 2012

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)

artículo científico publicado en 2020

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

scientific article published on 25 November 2019

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma

scientific article published on 18 May 2020

The Response to Second-line Induction with Bortezomib and Dexamethasone is Predictive of Long-term Outcomes Prior to High-dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma ⬇️

artículo científico publicado el 1 de enero de 2013

Trisomy 8 Involved in Myelodysplastic Syndromes as a Risk Factor for Intestinal Ulcers and Thrombosis — Behçet's Syndrome ⬇️

artículo científico publicado el 1 de junio de 2001

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

scientific article published on 08 April 2020

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma

artículo científico publicado en 2018

Lista de obras de

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model ⬇️

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma

Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression ⬇️

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.

Chronic Invasive Fungal Rhinosinusitis with Atypical Clinical Presentation in an Immunocompromised Patient

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations

Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis ⬇️

Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array ⬇️

Cyclosporine A for Chemotherapy-Resistant Subcutaneous Panniculitis-Like T Cell Lymphoma with Hemophagocytic Syndrome ⬇️

Cytogenetic analysis of de novo CD5‐positive diffuse large B‐cell lymphoma ⬇️

Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome ⬇️

Deletion or methylation ofCDKN2A/2BandPVT1rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality ⬇️

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.

Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease

Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab ⬇️

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma

Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma

Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.

Frequent PVT1 Rearrangement and Novel Chimeric Genes PVT1-NBEA and PVT1-WWOX Occur in Multiple Myeloma with 8q24 Abnormality ⬇️

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

Hematopoietic progenitor cell mobilization using low‐dose cyclophosphamide and granulocyte colony‐stimulating factor for multiple myeloma ⬇️

Identification of IGHCδ–BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B‐cell lymphoma/leukemia ⬇️

Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients

Intravascular B-cell lymphoma with hypercalcemia as the initial presentation ⬇️

Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma

Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia

NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients

Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy

Pure red cell aplasia caused by parvovirus B19 in two patients without chronic hemolysis ⬇️

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma ⬇️

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma

The Response to Second-line Induction with Bortezomib and Dexamethasone is Predictive of Long-term Outcomes Prior to High-dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma ⬇️

Trisomy 8 Involved in Myelodysplastic Syndromes as a Risk Factor for Intestinal Ulcers and Thrombosis — Behçet's Syndrome ⬇️

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma